HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
BHP Shares Fall as Jansen Potash Project Costs Surge 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
 of January 22, 2016 Lead Plaintiff Deadline - EconoTimes)
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors with losses over $50,000 of the January 22, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against Osiris Therapeutics, Inc. (NASDAQ:OSIR).
If you suffered losses because of your purchase of Osiris securities between May 12, 2014 and November 20, 2015, contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling (510) 725-3000, emailing [email protected] or visiting https://www.hbsslaw.com/cases/OSIR. The lawsuit was filed in the U.S. District Court for the District of Maryland and investors have until January 22, 2016 to move the court to act as lead plaintiff.
The complaint accuses the defendants of violations of the securities laws because Osiris failed to disclose during the Class Period that the Company overstated revenues from several contracts and failed to follow Generally Accepted Accounting Principles.
The news shocked investors when announced on November 16, 2015. Osiris disclosed that if they correctly recognized revenue for three contracts, it would result in substantial decreases in product revenues in 2014 and the first and second quarters of 2015. In addition, Osiris announced that these restatements would result in the Company missing its revenue targets in three of the last four quarters. Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.
If you lost more than $50,000 in your investments in Osiris securities between May 12, 2014 and November 20, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.
Whistleblowers: Persons with non-public information regarding Osiris should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at (510) 725-3000 or email [email protected].
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter at http://www.hbsslaw.com/hagens-berman-investor-fraud-center/securitites-newsletter, and visit the blog at www.meaningfuldisclosure.com.
